VBL Therapeutics to Present Data on its MOSPD2 Oncology Program at MIXiii-BIOMED 2018 on May 15

TEL AVIV, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will present data on its novel MOSPD2 program at the 17th MIXiii-BIOMED 2018 Conference and Exhibition, to be held May 15-17, 2018 in Tel Aviv, Israel.

Presentation Details:

Track entitled:Next Generation Oncology Treatments
Abstract Title:MOSPD2: A Novel Target for Antibody-Mediated Killing of Tumor Cells
Date: Tuesday, May 15, 2018
Time:16:00  - 16:15 IDT
Session Location:Hall A

For more information on the 17th MIXiii-BIOMED 2018 Conference and Exhibition refer to http://kenes-exhibitions.com/biomed/.

About MOSPD2
MOSPD2 is a novel tumor-related target identified by VBL that may be used as a marker for selective targeting of several types of tumors. Research conducted by VBL has shown that MOSPD2 is a novel membrane protein found on tumor cells that is present when they start invading tissues or creating metastatic lesions.  The Company believes that targeting of MOSPD2 may have several therapeutic applications, including inhibition of tumor cell metastases and targeting of MOSPD2-positive tumor cells. There are also potential applications in the inhibition of monocyte migration in chronic inflammatory conditions. VBL is developing the VB-600 series of pipeline candidates towards these applications.

About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. VB-111 is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer. VBL's deep pipeline also comprises the Lecinoxoids platform of anti-inflammatory molecules, and the VB-600 series of biologic agents targeting MOSPD2 for immune and oncology applications.  In October 2017, VBL opened its new gene therapy manufacturing plant in Modiin, Israel. The Modiin facility is the first commercial-scale gene therapy manufacturing facility in Israel and currently one of the largest gene-therapy designated ones in the world (20,000 sq. ft.).

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding VB-111, VB-600 and the MOSPD2 target, including their clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2017. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Michael Rice
LifeSci Advisors
(646) 597-6979